| Ident. | Authors (with country if any) | Title |
|---|
| 000532 |
I. Castrej N [États-Unis] ; M. Dougados [France] ; B. Combe [France] ; F. Guillemin [France] ; B. Fautrel [France] ; T. Pincus [États-Unis] | THU0165 Predictive Value of Different Remission Criteria for a Good Functional Status Outcome: Results from the Espoir Cohort |
| 000533 |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; F. Guillemin [France] ; B. Fautrel [France] | THU0134 Favorable Outcome, a New Concept for the Evaluation of Health Status in Rheumatoid Arthritis (RA) not so Easy to Achieve: Results from the Espoir Cohort |
| 000537 |
M. Dougados [France] ; K. Kissel [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; T. W. J. Huizinga [Pays-Bas] | THU0093 Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study |
| 000551 |
J. Sieper [Allemagne] ; B. Porter-Brown [Royaume-Uni] ; L. Thompson [Royaume-Uni] ; O. Harari [Royaume-Uni] ; M. Dougados [France] | OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial |
| 000554 |
T. W. J. Huizinga [Pays-Bas] ; T. Donka [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; M. Dougados [France] | OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study |
| 000558 |
C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; B. Fautrel [France] | FRI0415 Being younger and living with a partner are important determinants of sustained favorable outcome in early arthritis (EA): Results from the french espoir cohort |
| 000560 |
M. Schiff [États-Unis] ; M. Dougados [France] ; R. Fleischmann [États-Unis] ; J. Fay [États-Unis] ; M. Maldonado [États-Unis] | FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons |
| 000569 |
P. Emery [Royaume-Uni] ; R. Westhovens [Belgique] ; M. Dougados [France] ; R. Alten [Allemagne] ; C. Gaillez ; C. Poncet [France] ; M. Le Bars ; A. Elegbe ; H. Genant [États-Unis] | FRI0199 In patients with established RA, abatacept efficacy is independent of baseline annual radiographic progression rate |
| 000571 |
E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | FRI0183 Sustained inhibition of structural damage in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors prior to rituximab treatment: 5-year data from the reflex study |
| 000573 |
I. Castrejon [États-Unis] ; T. Pincus [États-Unis] ; M. Soubrier [France] ; Y. C. Lin [États-Unis] ; M. Dougados [France] | FRI0077 Relative efficiencies of joint counts and laboratory tests are no higher than patient-reported measures to document superior results in the guepard tight-control versus espoir routine care cohorts |
| 000576 |
P. A. Natella ; A. Hesbert ; A. Nivina ; E. Dahan ; V. Seynave ; E. Bouscarrut ; L. Gossec [France] ; C. Roux [France] ; M. Dougados [France] ; E. Flipon | AB1413 PHA-BRIC: Therapeutic information of rheumatology patients receiving biologics in cochin hospital |
| 000581 |
J. Smolen [Autriche] ; M. Dougados [France] ; C. Gaillez ; C. Poncet [France] ; M. Le Bars ; A. Elegbe ; M. Schiff [États-Unis] | AB0543 Remission using different composite disease indices in MTX-IR RA patients treated with abatacept or infliximab, +MTX |
| 000585 |
E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study |
| 000586 |
B. Combe [France] ; M. Dougados [France] ; I. Logeart ; C. Lukas [France] ; X. Mariette [France] ; X. Puechal ; A. Saraux ; T. Schaeverbeke [France] | AB0516 An open-label randomized controlled study to evaluate the efficacy of etanercept (ETN) versus rituximab (RTX), in patients with active rheumatoid arthritis previously treated with RTX and TNF blockers |
| 000590 |
M. Boers [Pays-Bas] ; Y. Brault [France] ; I. Logeart [France] ; M. Dougados [France] | AB0306 The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept |
| 000629 |
L. Gossec [France] ; J S Smolen [Autriche] ; C. Gaujoux-Viala [France] ; Z. Ash [Royaume-Uni] ; H. Marzo-Ortega [Royaume-Uni] ; D. Van Der Heijde [Pays-Bas] ; O. Fitzgerald [Irlande (pays)] ; D. Aletaha [Autriche] ; P. Balint [Hongrie] ; D. Boumpas [Grèce] ; J. Braun [Allemagne] ; F C Breedveld [Pays-Bas] ; G. Burmester [Allemagne] ; J D Ca Ete [Espagne] ; M. De Wit [Suisse] ; H. Dagfinrud [Norvège] ; K. De Vlam [Belgique] ; M. Dougados [France] ; P. Helliwell [Royaume-Uni] ; A. Kavanaugh [États-Unis] ; T K Kvien [Norvège] ; R. Landewé [Pays-Bas] ; T. Luger [Allemagne] ; M. Maccarone [Italie] ; D. Mcgonagle [Royaume-Uni] ; N. Mchugh [Royaume-Uni] ; I B Mcinnes [Royaume-Uni] ; C. Ritchlin [États-Unis] ; J. Sieper [Allemagne] ; P P Tak [Pays-Bas] ; G. Valesini [Italie] ; J. Vencovsky [République tchèque] ; K L Winthrop [États-Unis] ; A. Zink [Allemagne] ; P. Emery [Royaume-Uni] | European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies |
| 000672 |
S. Van Assen [Pays-Bas] ; N. Agmon-Levin [Israël] ; O. Elkayam [Israël] ; R. Cervera [Espagne] ; M F Doran [Irlande (pays)] ; M. Dougados [France] ; P. Emery [Royaume-Uni] ; P. Geborek [Suède] ; J P A. Ioannidis [États-Unis, Grèce] ; D R W. Jayne [Royaume-Uni] ; C G M. Kallenberg [Pays-Bas] ; U. Müller-Ladner [Allemagne] ; Y. Shoenfeld [Israël] ; L. Stojanovich [Serbie] ; G. Valesini [Italie] ; N M Wulffraat [Pays-Bas] ; M. Bijl [Grèce] | EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases |
